

# **Entereg<sup>®</sup> (alvimopan)**

## **Postoperative Ileus, A Surgical Perspective**

---

**Anthony Senagore, MD, MS, MBA**

**Professor of Surgery, Michigan State University**

**VP, Research and Education, Spectrum Health,  
Grand Rapids, MI**

## Magnitude of the Problem

---

- ⌘ Approximately 400,000 patients undergo small and large bowel resection each year<sup>a</sup>
  - 90% open surgery, 10% laparoscopic<sup>b</sup>
  - ALL of these patients experience POI of some degree
  - At least 10% to 15% require intervention or a change in hospital management due to unresolving POI
  - Prolonged POI CANNOT be reliably predicted before bowel resection surgery

<sup>a</sup> Premier Inc. Procedural Data, 2006 Projections.

<sup>b</sup> Hinojosa MW. *J Gastrointest Surg.* 2007;11:423-429.

## Definition and Clinical Signs

---

- ❖ Transient cessation of coordinated bowel motility after surgery preventing effective transit of intestinal contents and/or tolerance of oral intake<sup>a</sup>
- ❖ No physiological benefit of POI
- ❖ Clinical signs
  - Nausea/vomiting
  - Absence of passage of flatus/stool
  - Bloating, abdominal pain, discomfort

<sup>a</sup> Delaney C, et al. In: Bosker G, ed. *Clinical Consensus Update in General Surgery*. Roswell, Ga: Pharmatecture, LLC; 2006. <http://www.clinicalwebcasts.com/updates/index.htm>.

# Etiology

---

## ❖ Surgical stress response

- Neurogenic<sup>a</sup>
- Hormones and neuropeptides<sup>b</sup>
- Inflammatory mediators<sup>c,d</sup>

## ❖ Surgical anesthesia

- Many impair GI motility<sup>e,f,g</sup>
- Primary effect on colon<sup>f</sup>

<sup>a</sup> Holzer P, et al. *Neuroscience*. 1992;48:715-722; <sup>b</sup> Zittel TT, et al. *Surgery*. 1998;123:518-527;

<sup>c</sup> Moojen TM, et al. *Neurogastroenterol Motil*. 1999;11:403-408; <sup>d</sup> Kalff JC, et al. *Gastroenterology*. 2000;118:316-327;

<sup>e</sup> Ogilvy AJ, et al. *Eur J Anaesthesiol*. 1995;10 Suppl:35-42; <sup>f</sup> Condon RE, et al. *Surgery*. 1987;101:81-85;

<sup>g</sup> Freye E, et al. *Acta Anaesthesiol Scand*. 1998;42:664-669.

## Etiology— Opioid Analgesic Agents

---

- ⌘ Bind to  $\mu$ -opioid receptors within the enteric nervous system<sup>a</sup>
- ⌘ Block excitatory neurons innervating intestinal smooth muscle<sup>b</sup>
- ⌘ Inhibit GI motility<sup>a,b,c</sup>

<sup>a</sup> Austrup ML, et al. *Surg Clin North Am.* 1999;79:253-273.

<sup>b</sup> Bauer AJ, et al. *Gastroenterology.* 1991;101:970-976.

<sup>c</sup> Kaufman PN, et al. *Gastroenterology.* 1988;94:1351-1356.

## Patient-Controlled Analgesia (PCA)

---

- ❖ Opioid-based PCA standard care for pain management following bowel resection<sup>a,b</sup>
  - More effective analgesia
  - Shorter hospital stay
  - Improved patient satisfaction
- ❖ Associated with higher incidence of “coded” POI<sup>c</sup>

<sup>a</sup> Ballantyne JC, et al. *J Clin Anesth.* 1993;5:182-193.

<sup>b</sup> Petros JG, et al. *Am J Surg.* 1995;170:371-374.

<sup>c</sup> Goettsch WG, et al. *Pharmacoepidemiol Drug Saf.* 2007;16:668-674.

# Gastrointestinal Recovery— How Long Is Too Long?

---

- ❖ GI recovery after 5 days increases risk of
  - Prolonged hospital length of stay (LOS)<sup>a,b</sup>
  - Morbidity, including nosocomial infections<sup>c</sup>
  - Medical or surgical intervention

<sup>a</sup> Person B, et al. *Curr Prob Surg.* 2006;43:6-65; <sup>b</sup>Delaney CP, et al. *Br J Surg.* 2001;88:1533-1538;

<sup>c</sup>Buchner AM, et al. *Dig Dis Sci.* 2002;47:201-207.

## **Gastrointestinal Recovery— How Long Is Too Long?**

---


- ❖ For this reason, the primary clinical objective following BR is avoidance of POI**
- ❖ Most studies in the area of perioperative care protocols are powered based on a 1-day reduction in length of stay, by accelerating recovery of bowel function**

# Patient Characterization

---



# Overall Healthcare Burden Associated With POI<sup>a,b,c,d</sup>




<sup>a</sup> Schuster TG, Montie JE. *Urology*. 2002;59:465. <sup>b</sup> Holte K, Kehlet H. *Br J Surg*. 2000;87:1480.

<sup>c</sup> Chang SS, et al. *J Urol*. 2002;67:208; <sup>d</sup> Sarawate CA, et al. *Gastroenterology*. 2003;124:A-828.


# Length of Hospital Stay and Associated Costs Increase With Coded POI

## Premier's Perspective Database



\* $p < 0.01$  for coded POI vs no coded POI.  
Senagore A, et al. Presented at ASHP, June 2006.

# In-Hospital Mortality Associated With POI Premier's Perspective Database



\* $p < 0.01$  for coded POI vs no coded POI.  
Senagore A, et al. Presented at ASHP, June 2006.

# POI—Current Treatment Options

---

- ❖ **Multimodal accelerated care pathways**
  - Intensive nursing and physician input
  - Early NG tube removal, diet advancement, ambulation
  - Opioid-sparing analgesia
  - Prokinetics—none approved for POI
  - Minimally invasive surgery

# Prophylaxis of POI Versus DVT/Surgical Site Infection

---

	<b>NNT</b>
<b>DVT/surgical site infection<sup>a</sup></b>	<b>4 - 17</b>
<b>POI (discharge order written before Day 7)</b>	<b>5 - 9</b>

<sup>a</sup> Song F. *Health Technol Assess.* 1998;2:1-111.  
Anderson DR, et al. *Ann Intern Med.* 1993;119:1105-1112.  
Wells PS, et al. *Arch Intern Med.* 1994;154:67-72.

## POI—Current Unmet Need

---

- ❖ No approved drugs for management of POI
- ❖ Current management options limited and not consistently effective
- ❖ No reliable criteria to predict who will develop prolonged or severe POI
- ❖ POI should be managed proactively in patients undergoing bowel resection